Astrazeneca (AZNCF) Receivables Refunds (2016 - 2025)
Historic Receivables Refunds for Astrazeneca (AZNCF) over the last 16 years, with Q4 2025 value amounting to $1.4 billion.
- Astrazeneca's Receivables Refunds fell 2517.48% to $1.4 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $1.4 billion, marking a year-over-year decrease of 2517.48%. This contributed to the annual value of $1.4 billion for FY2025, which is 2517.48% down from last year.
- According to the latest figures from Q4 2025, Astrazeneca's Receivables Refunds is $1.4 billion, which was down 2517.48% from $1.2 billion recorded in Q3 2025.
- Astrazeneca's 5-year Receivables Refunds high stood at $1.9 billion for Q4 2024, and its period low was $347.0 million during Q1 2021.
- Moreover, its 5-year median value for Receivables Refunds was $785.5 million (2022), whereas its average is $977.4 million.
- As far as peak fluctuations go, Astrazeneca's Receivables Refunds skyrocketed by 21637.24% in 2021, and later plummeted by 3644.44% in 2025.
- Astrazeneca's Receivables Refunds (Quarter) stood at $663.0 million in 2021, then rose by 10.26% to $731.0 million in 2022, then skyrocketed by 95.08% to $1.4 billion in 2023, then soared by 30.36% to $1.9 billion in 2024, then dropped by 25.17% to $1.4 billion in 2025.
- Its Receivables Refunds was $1.4 billion in Q4 2025, compared to $1.2 billion in Q3 2025 and $1.0 billion in Q2 2025.